Catalyst settles Firdapse patent litigation with Hetero, bars US generic until 2035

Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

CPRX

0.00
  • Catalyst Pharmaceuticals reached a settlement with Hetero Labs to end patent litigation tied to Hetero’s ANDA for a generic version of FIRDAPSE (amifampridine) 10 mg tablets.
  • Deal grants Hetero a license to launch a US generic no earlier than a specified date in January 2035, subject to customary exceptions.
  • Parties will terminate the New Jersey federal court case ahead of a May 18, 2026 trial date.
  • Settlement clears remaining FIRDAPSE patent litigation, following earlier deals with Lupin, Teva, and Inventia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070244PRIMZONEFULLFEED9715292) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.